Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment

INTRODUCTION: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosoda, Shunichi, Suda, Goki, Sho, Takuya, Ogawa, Koji, Kimura, Megumi, Yang, Zijian, Yoshida, Sonoe, Kubo, Akinori, Tokuchi, Yoshimasa, Kitagataya, Takashi, Maehara, Osamu, Ohnishi, Shunsuke, Nakamura, Akihisa, Yamada, Ren, Ohara, Masatsugu, Kawagishi, Naoki, Natsuizaka, Mitsuteru, Nakai, Masato, Morikawa, Kenichi, Furuya, Ken, Baba, Masaru, Yamamoto, Yoshiya, Suzuki, Kazuharu, Izumi, Takaaki, Meguro, Takashi, Terashita, Katsumi, Ito, Jun, Miyagishima, Takuto, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267515/
https://www.ncbi.nlm.nih.gov/pubmed/37325489
http://dx.doi.org/10.1159/000527759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267515/
https://www.ncbi.nlm.nih.gov/pubmed/37325489
http://dx.doi.org/10.1159/000527759

Ejemplares similares